SCHEMBL24149191

SCHEMBL24149191

CC(=O)c1cc2cc(C(=O)O)[nH]c2cc1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.69
SMAD3 P84022 1/20 0.51
PIN1 Q13526 1/20 0.50
EIF4A3 P38919 2/20 0.48
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
LMNA P02545 2/20 0.46
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
PDPK1 O15530 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SRD5A2 P31213 2/20 0.46
MAPT P10636 2/20 0.46
DAO P14920 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15223899 0.90 GPR35 (0.53) GPR35SMAD3PIN1HPGDLMNA
SCHEMBL12392285 0.83 GPR35 (0.46) GPR35SMAD3PIN1LMNAMAPT
SCHEMBL25721356 0.83 XDH (0.47) GPR35KDM4EHPGDHSD17B10LMNA
SCHEMBL49512 0.82 GPR35 (1.00) GPR35SMAD3PIN1EIF4A3KDM4E
SCHEMBL19400491 0.80 HPGD (0.45) GPR35KDM4EHPGDHSD17B10LMNA
SCHEMBL7040376 0.79 GPR35 (0.73) GPR35SMAD3PIN1EIF4A3KDM4E
SCHEMBL29461453 0.78 GPR35 (0.66) GPR35SMAD3PIN1EIF4A3KDM4E
SCHEMBL28706307 0.78 GPR35 (0.66) GPR35SMAD3PIN1EIF4A3KDM4E
SCHEMBL15623148 0.78 GPR35 (0.47) GPR35SMAD3PIN1EIF4A3KDM4E
SCHEMBL22129956 0.76 GPR35 (0.63) GPR35SMAD3PIN1EIF4A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023118961-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF INTOCELL, INC. (KR) 2023-06-29 WO disclosed
US-20230190939-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF INTOCELL, INC. (KR) 2023-06-22 US disclosed
US-20230190939-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF INTOCELL, INC. (KR) 2023-06-22 US disclosed
WO-2021260438-A1 ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES INTOCELL, INC. (KR) 2021-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190939-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF CD47, ENPP2, CD2 GPR35 3119/4885SMAD3 1226/4885PIN1 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.